First bulk wholesale deal for MMJ Phytotech

Published at Nov 19, 2015, in ASX Biotechs

MMJ Phytotech (ASX:MMJ) has bagged its first wholesale sale of its Satipharm CBD pill, a sale which could open doors for the pharmaceutical player.

It told the market today that it had secured a $225,000 sale to UK supplement distributor Prima Sport, with the pill to be sold through a dedicated portal on the Prima Sport website.

MMJ said it expects the order to be sold to customers within the first half of next year and it was in discussions with other European companies about doing a similar deal.

“This partnership with Prima Sport, a leading supplement distributor, provides MMJ with access to a larger market within the United Kingdom and has the potential to raise further awareness of our CBD capsules,” MMJ managing director Andreas Gedeon said.

“This agreement also opens up further opportunities with Prima Sport and other distributors to wholesale further products and accelerate our wholesale strategy.”

MMJ first bagged a sale of its CBD pill back at the end of August, but this was from its own website rather than a wholesale bulk deal.

MMJ has also recently signalled that it intends to pursue a market entry in Australia on the back of regulatory wins in several states.

The pharmaceutical company raised $2 million to fund the market entry, but further bulk wholesale deals could provide a step-change in revenue for the company and fund further entries or acquisitions.

About MMJ Phytotech

The ‘farm to pharma’ company grows cannabis plants in Canada to extract the vital medicinal ingredients from the plant.

It then sends them off to Switzerland, where its subsidiary Satipharm develops products such as the CBD pill from them.

It also has its eyes on being a pharmaceutical developer and distributor of cannabinoid “Active Pharmaceutical Ingredients” (APIs), which are highly valuable and for cannabinoid (CBD), can be traded at prices upwards of $350,000 per kilogram.

It also has a R&D offshoot in Israel which works on research and product development.

View Our Investment Portfolios

S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.

Conflict of Interest Notice

S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.

Publishers Notice

The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.

Australian ASX Small Cap stocks | Why is Australia’s leading small cap publication

Founded seven years ago, is Australia’s leading and longest standing website for investor and finance news, education and expert opinion.

Published by StocksDigital, Finfeed was created to report daily on the comings and goings of ASX listed stocks in the small cap market.

As the first digital publication dedicated specifically to this space, Finfeed soon became the most trusted publication in the market, quickly garnering over two million page views – a number that continues to rise. provides its readers with informative articles that tackle the latest in market moving #ASX small cap news, plus exclusive content you won’t find anywhere else. It is aimed at those with an interest in investing, market education, company performance, start-ups and much more. is the only media organisation operating under the strength of a Financial Services License and is backed by leading journalists and analysts all with brands of their own.

The website aims to inform, educate and entertain with content that drills down into the heart of financial matters.

Finfeed is a leading source of investor and market information, with everything investors need to know about how to invest written in a way that anyone can understand. 

Over the years, the website has expanded beyond exclusively reporting on small caps, to profile Australia’s leading ASX listed small, mid and large caps as well as some of the country’s most successful CEOs and business leaders to find out what makes them tick.

Every day you will find fresh content covering:

Fast Facts

Over 4,000 articles published

Over 2.3 Million Page Views and counting

Over 10,000 followers on social media

Subscriber list growing by 2% monthly

Thanks for subscribing!